HomeCompareKYSEY vs ABBV

KYSEY vs ABBV: Dividend Comparison 2026

KYSEY yields 2.90% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KYSEY wins by $219.6K in total portfolio value· pulled ahead in Year 6
10 years
KYSEY
KYSEY
● Live price
2.90%
Share price
$11.38
Annual div
$0.33
5Y div CAGR
54.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$321.9K
Annual income
$171,146.98
Full KYSEY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KYSEY vs ABBV

📍 KYSEY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKYSEYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KYSEY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KYSEY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KYSEY
Annual income on $10K today (after 15% tax)
$246.49/yr
After 10yr DRIP, annual income (after tax)
$145,474.93/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KYSEY beats the other by $124,418.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KYSEY + ABBV for your $10,000?

KYSEY: 50%ABBV: 50%
100% ABBV50/50100% KYSEY
Portfolio after 10yr
$212.1K
Annual income
$97,959.37/yr
Blended yield
46.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KYSEY
No analyst data
Altman Z
0.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KYSEY buys
0
ABBV buys
0
No recent congressional trades found for KYSEY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKYSEYABBV
Forward yield2.90%3.06%
Annual dividend / share$0.33$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.4%40.6%
Portfolio after 10y$321.9K$102.3K
Annual income after 10y$171,146.98$24,771.77
Total dividends collected$285.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KYSEY vs ABBV ($10,000, DRIP)

YearKYSEY PortfolioKYSEY Income/yrABBV PortfolioABBV Income/yrGap
1$11,148$447.73$11,550$430.00$402.00ABBV
2$12,648$720.23$13,472$627.96$824.00ABBV
3$14,713$1,179.17$15,906$926.08$1.2KABBV
4$17,722$1,979.28$19,071$1,382.55$1.3KABBV
5$22,403$3,440.22$23,302$2,095.81$899.00ABBV
6← crossover$30,246$6,275.36$29,150$3,237.93+$1.1KKYSEY
7$44,589$12,225.68$37,536$5,121.41+$7.1KKYSEY
8$73,718$26,007.23$50,079$8,338.38+$23.6KKYSEY
9$140,922$62,043.93$69,753$14,065.80+$71.2KKYSEY
10$321,933$171,146.98$102,337$24,771.77+$219.6KKYSEY

KYSEY vs ABBV: Complete Analysis 2026

KYSEYStock

Kyushu Electric Power Company, Incorporated engages in the power generation, transmission, distribution, and sales in Japan and internationally. The company operates through Domestic Electric Power, Other Energy Service, ICT Service, and Other segments. It generates electricity from nuclear, thermal, hydroelectric, geothermal, internal combustion, wind, solar, poultry dung fuel, and biomass power energy sources. The company also receipts, stores, vaporizes, delivers, and sells LNG; purchases, operates, charters, and rents LNG carriers; manufactures and sells electric machinery, specialist equipment, concrete poles, HV and LV insulators, and other products; constructs, maintains, and repairs power generation facilities; buys, leases, manages, cleans, and maintains real estate properties; acquires and owns securities; recycles used confidential documents; and offers geothermal technical and air cargo transportation services, as well as housing and building reviews, assessments and guarantees. In addition, it installs, maintains, and manages electrical measurement equipment; and manufactures, installs, and maintains steel structures. Further, the company offers telecommunication devices, and fiber-optic cable and broadband services; elderly nursing home management and nursing, temporary staffing, and job-placement services; information systems; and computer software. Additionally, it is involved in the heat supply activities; environmental preservation work; consultation, planning, investigation, measurement, design, drafting, and care of civil engineering/construction projects; clerical work acceptance on trust and consulting business; data center business; investment activities; Internet website planning, development, and management; planning and operation of e-sports; management of golf courses; subtitle production for broadcasting; and ownership of mining interests and assets. The company was incorporated in 1951 and is headquartered in Fukuoka City, Japan.

Full KYSEY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KYSEY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KYSEY vs SCHDKYSEY vs JEPIKYSEY vs OKYSEY vs KOKYSEY vs MAINKYSEY vs JNJKYSEY vs MRKKYSEY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.